vTv Therapeutics Inc (NASDAQ:VTVT) saw a significant decline in short interest during the month of May. As of May 15th, there was short interest totalling 977,984 shares, a decline of 32.3% from the April 30th total of 1,444,136 shares. Approximately 14.0% of the shares of the stock are short sold. Based on an average trading volume of 1,462,831 shares, the short-interest ratio is presently 0.7 days.

Shares of vTv Therapeutics traded up $0.04, reaching $1.69, during midday trading on Thursday, Marketbeat.com reports. The company had a trading volume of 203,000 shares, compared to its average volume of 1,157,070. The company has a debt-to-equity ratio of -0.09, a current ratio of 0.35 and a quick ratio of 0.35. The firm has a market cap of $59.41 million, a P/E ratio of -1.01 and a beta of 1.84. vTv Therapeutics has a 1-year low of $0.65 and a 1-year high of $8.40.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings results on Tuesday, May 15th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). The company had revenue of $2.06 million for the quarter, compared to analyst estimates of $3.14 million. sell-side analysts expect that vTv Therapeutics will post -1.19 EPS for the current year.

VTVT has been the subject of a number of research analyst reports. Zacks Investment Research upgraded shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, April 13th. ValuEngine upgraded shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Roth Capital initiated coverage on shares of vTv Therapeutics in a research note on Thursday, March 8th. They issued a “buy” rating and a $17.00 target price for the company. Northland Securities cut shares of vTv Therapeutics from an “outperform” rating to a “market perform” rating and set a $28.00 target price for the company. in a research note on Tuesday, April 10th. Finally, Seaport Global Securities initiated coverage on shares of vTv Therapeutics in a research note on Thursday, March 29th. They issued a “buy” rating and a $14.00 target price for the company. Seven investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. vTv Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $13.09.

In other news, major shareholder Ronald O. Perelman bought 570,776 shares of the business’s stock in a transaction dated Thursday, May 24th. The stock was bought at an average price of $4.38 per share, for a total transaction of $2,499,998.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.00% of the company’s stock.

Several institutional investors have recently modified their holdings of the stock. Millennium Management LLC increased its holdings in shares of vTv Therapeutics by 51.6% in the first quarter. Millennium Management LLC now owns 95,031 shares of the biotechnology company’s stock valued at $387,000 after purchasing an additional 32,362 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in vTv Therapeutics by 55.9% during the 1st quarter. JPMorgan Chase & Co. now owns 327,728 shares of the biotechnology company’s stock worth $1,333,000 after acquiring an additional 117,513 shares during the period. C WorldWide Group Holding A S acquired a new stake in vTv Therapeutics during the 1st quarter worth $399,000. Royce & Associates LP acquired a new stake in vTv Therapeutics during the 4th quarter worth $1,352,000. Finally, Creative Planning acquired a new stake in vTv Therapeutics during the 4th quarter worth $114,000. 15.04% of the stock is owned by institutional investors and hedge funds.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.